MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Lunit, an AI for cancer diagnostics provider and Labcorp, an innovative laboratory service provider, have announced a strategic collaboration to expand AI-powered digital pathology research, combining Labcorp’s large-scale tissue datasets with Lunit’s AI models for slide interpretation. The partnership will focus on improving biomarker discovery, refining diagnostic accuracy and supporting translational research in oncology. Lunit’s algorithms will be applied to Labcorp’s scanned pathology slides to analyze tumor microenvironments, quantify biomarkers and identify patterns that may guide treatment selection. The companies say the work will support both early-stage research and future clinical study design.
The move highlights increasing adoption of AI in histopathology, where digitization and high-throughput image analysis are now central to cancer research. Labcorp’s extensive specimen network may give the partnership a unique advantage in scale and diversity of training data. The collaboration aims to broaden cancer and genomic correlations through the application of AI and digital pathology.
Posted by MedCloudInsider Editors on 11/17/20250 comments
Leucid Bio, a biotechnology company dedicated to the development of cell therapies, has shared an update from its ongoing Phase I/IIa AERIAL clinical trial evaluating LEU011, a Lateral CAR-T therapy targeting NKG2D ligands in advanced solid tumors. Interim results show sustained partial responses and evidence of immune persistence in patients with recurrent or metastatic head and neck squamous cell carcinoma. The treatment demonstrated a manageable safety profile with no new dose-limiting toxicities.
The findings mark progress for CAR-T therapies in solid tumors, a field long constrained by tumor microenvironment challenges. Leucid’s “lateral” CAR architecture—designed to improve T-cell persistence and tumor penetration—could represent a breakthrough in solid tumor immunotherapy. Full Phase II results are expected in the first half 2026.
Posted by MedCloudInsider Editors on 11/10/20250 comments
Co-Diagnostics (Co-Dx), a molecular diagnosis company, announced plans to integrate its proprietary artificial intelligence algorithms into the Co-Dx Primer AI Platform, designed to accelerate PCR diagnostics. The AI component will analyze genomic data to identify optimal primer and probe sequences, reducing design time and enhancing specificity. The integration aims to support diagnostic applications in infectious diseases, oncology and other molecular testing markets.
The move highlights the growing use of AI in molecular diagnostics. Co-Diagnostics’ proprietary integration targets low-cost, rapid test development in both clinical and field environments. The models will function together with the Co-Dx cloud platform and internal databases to form the foundation of Co-Dx Primer AI.
Posted by MedCloudInsider Editors on 11/04/20250 comments
Bio-Techne, a global provider of life science tools and diagnostic products along with Nucleai, have announced an AI-powered spatial biology workflow designed to accelerate predictive biomarker discovery in melanoma research. The integrated solution uses AI and biotechnology for effective treatment options personalized to the patient's needs. Early results indicate improved accuracy in identifying biomarkers linked to patient response to immunotherapy.
The partnership highlights AI’s expanding role in oncology diagnostics. By combining imaging chemistry with machine learning, Bio-Techne and Nucleai aim to enable translational researchers to move from static tissue profiling to predictive, patient-specific biomarker discovery.
Posted by MedCloudInsider Editors on 11/04/20250 comments
AIxMed dedicated to transforming cancer diagnosis and monitoring, together with PathNet, a digital pathology laboratory, has formed a strategic partnership to deploy an AI-powered urine cytology workflow designed to enhance early detection of bladder cancer. The system integrates AIxMed’s AIxURO™ technology with PathNet’s digital pathology network, allowing for automated cytology slide review and classification. The collaboration aims to reduce diagnostic variability, improve turnaround times and support hospitals transitioning from manual to AI-augmented pathology.
The partnership reflects growing adoption of AI in clinical diagnostics. The AIxMed-PathNet alliance focuses specifically on cytology—a diagnostic area historically underserved by digital tools. AIxURO™ assists with the analysis of non-invasive urine cytology specimens to improve diagnostic accuracy of bladder cancer. The collaboration is aimed towards efficiency, enhancement and overall diagnostic improvement.
Posted by MedCloudInsider Editors on 11/04/20250 comments
Labviva, a leading AI-powered source-to-pay provider for life sciences, has launched its Smart Suppliers of the Future program to accelerate digital transformation in life sciences procurement. The initiative enables suppliers to digitalize their offerings and expand their reach through Labviva's supplier network. The move expands Labviva’s marketplace to over 15 million products from 18,000 manufacturers, representing 90 percent of life sciences suppliers across the U.S. and Europe.
Labviva’s network-driven approach, linking suppliers of all sizes through AI insights and real-time pricing, positions it as a leading “Amazon-style” marketplace for scientific materials. Its AI-driven insights allow no-touch forecasting, automated inventory replenishment and seamless regulatory compliance. The aim of the platform is a frictionless supply chain that accelerates scientific discovery and source-to-pay processes.
Posted by MedCloudInsider Editors on 10/27/20250 comments
Harvard Health Publishing (HHP), part of Harvard Medical School, has licensed its library of consumer health content to Microsoft to train Copilot, the company’s AI assistant. The data includes articles on disease prevention, nutrition and wellness, all reviewed by Harvard scientists and researchers. The goal is to enhance Copilot’s accuracy when responding to healthcare-related questions. Microsoft confirmed that it paid for the license.
The deal highlights a growing focus on using trusted medical sources to improve AI reliability. By leveraging peer-reviewed, clinically verified content, Microsoft aims to strengthen Copilot’s credibility in the sensitive domain of consumer health information. This license also makes content previously exclusive to HHP subscribers available to anyone who uses Microsoft Copilot.
Posted by MedCloudInsider Editors on 10/21/20250 comments
dQ&A focuses its research efforts on diabetes to produce a unique take on treatment plans. They have released a beta version of their AI Insights Platform, designed to give healthcare companies, researchers and policymakers faster access to data on the diabetes market.
Posted by MedCloudInsider Editors on 10/17/20250 comments
Microsoft has expanded Dragon Copilot, its ambient AI assistant for healthcare, to include the first commercially available version designed for nursing workflows. The update allows secure integration of partner-built AI applications and agents directly within Dragon Copilot, enabling clinicians to access tools for documentation, decision support and revenue cycle automation without leaving their workflow.
Partners include Elsevier, Wolters Kluwer, Atropos Health, Ensemble and Press Ganey, among others, offering embedded clinical references, revenue intelligence and patient engagement analytics. The expansion underscores Microsoft’s move toward an open AI ecosystem in healthcare. Dragon Copilot equips nurses with automating tasks, streamlining documentation and improving overall patient experience by assisting nurses suffering from administrative burnout. Microsoft’s extensible model signals a shift toward modular, multi-vendor AI at the point of care.
Posted by MedCloudInsider Editors on 10/17/20250 comments
Google has reported that its Gemma AI model contributed to the discovery of a new pathway that could inform cancer drug development. Using Gemma’s generative and predictive capabilities, researchers identified a novel interaction between protein signaling networks implicated in tumor growth. The findings mark one of the first demonstrations of foundation models accelerating early-stage biomedical discovery.
The breakthrough underscores AI’s expanding role in molecular biology. While in its early stages, this tool can mark the mark of powerful, experimentally validated leads for developing new combination therapies that use a combination method for more robust results. The C2S-Scale 27B model is available to the research community with a scientific preprint, the code and the actual model available online.
Posted by MedCloudInsider Editors on 10/15/20250 comments
Nobles Medical Technology 2, a provider of cardiovascular closure solutions, announced it received FDA approval to resume its NobleStitch EL clinical trial for patent foramen ovale (PFO) closure. The minimally invasive device uses a suture-only method to close the small opening between the heart’s upper chambers, offering a potential alternative to metal implants. The company paused enrollment earlier this year following requests for additional safety and performance data, which it says have now been addressed.
A Pre-Market Approval will be submitted upon completion of the study, with patient enrollments set to continue in the last quarter of 2025. The device utilizes a proprietary percutaneous suturing technique to close defects without requiring a permanent implant.
Posted by MedCloudInsider Editors on 10/07/20250 comments
ZEISS, one of the leading medical technology companies listed on the MDAX and TecDAX of the German stock exchange, expanded its ophthalmic portfolio with new surgical instruments and digital workflow capabilities aimed at improving efficiency and visualization in vitreoretinal surgery. The updates enhance integration between DORC devices and ZEISS’s digital surgery platforms, allowing real-time data capture and imaging within a connected ecosystem. The company said the expansion supports improved surgical precision and workflow standardization across operating rooms.
The announcement underscores ZEISS’s effort to lead in connected surgical ecosystems, the company said. This is an area seeing rapid digitalization. ZEISS’s combined focus on instrumentation and digital connectivity aims to differentiate it in the next phase of ophthalmic device innovations.
Posted by MedCloudInsider Editors on 10/07/20250 comments